BioCentury | Dec 2, 2020
Distillery Therapeutics

SQSTM1, INSR identified as targets in sepsis

DISEASE CATEGORY: Infectious disease INDICATION: Sepsis Inhibiting the scaffold protein SQSTM1 or its extracellular receptor INSR could treat bacterial sepsis. Among 40 patients with bacterial sepsis, survivors had lower peripheral blood mononuclear cell mRNA levels of SQSTM1...
BioCentury | Dec 2, 2020
Distillery Therapeutics

A phosphofructokinase inhibitor for a genetic mitochondrial syndrome

DISEASE CATEGORY: Endocrine/metabolic INDICATION: Mitochondrial disease A PFKM inhibitor could treat MELAS (mitochondrial encephalopathy, lactic acidosis and stroke-like episodes) syndrome, which is most often caused by mutations in mitochondrially encoded MT-TL1. A cell-based screen of 17,568 small...
BioCentury | Dec 2, 2020
Distillery Therapeutics

Apoptosis regulator MCL1 as an Alzheimer’s target

DISEASE CATEGORY: Neurology INDICATION: Alzheimer’s disease (AD) Blocking MCL1, which inhibits apoptosis, could treat Alzheimer’s disease. A high-throughput screen in HEK cells of 2,204 drug candidates or FDA-approved drugs yielded 20 agents, including an MCL1...
BioCentury | Oct 31, 2020
Distillery Therapeutics

TREML4 as a sepsis target

DISEASE CATEGORY: Infectious disease INDICATION: Sepsis Inhibiting the myeloid receptor TREML4 could treat sepsis. In mice with acute polymicrobial sepsis, systemic knockout of TREML4 prevented macroscopic thymic involution and increased proportions of mature and immature...
BioCentury | Oct 28, 2020
Distillery Therapeutics

Inhibiting IL-33-driven inflammation to treat brain cancer

DISEASE CATEGORY: Cancer INDICATION: Brain cancer Targeting nuclear accumulation of IL-33 could treat glioblastoma multiforme by reducing recruitment of pro-tumorigenic innate immune cells to the tumor microenvironment. In patients with glioblastoma multiforme, high expression of...
BioCentury | Oct 28, 2020
Distillery Therapeutics

LIMS1 identified as NSCLC target

DISEASE CATEGORY: Cancer INDICATION: Non-small cell lung cancer (NSCLC) Targeting the focal adhesion protein LIMS1 could treat NSCLC. In patients with lung adenocarcinoma, LIMS1 expression was higher in tumor tissue compared with normal lung tissue,...
BioCentury | Oct 27, 2020
Distillery Therapeutics

PCF11 binding site on E3 ubiquitin ligase MAGEA11 identified as neuroblastoma target

DISEASE CATEGORY: Cancer INDICATION: Neuroendocrine tumors Interrupting the interaction between the oncogenic E3 ubiquitin ligase MAGEA11 and its substrate PCF11 could treat neuroendocrine tumors. Crystallographic analysis of the MAGEA11-PCF11 complex identified a shallow cleft on...
BioCentury | Oct 27, 2020
Distillery Therapeutics

UCSF team develops trivalent binder of SARS-CoV-2 spike for COVID-19

DISEASE CATEGORY: Infectious disease INDICATION: Coronavirus A UCSF team led by Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS) founder Jim Wells has developed a trivalent immunoglobulin variable heavy domain-based inhibitor of the ACE2-SARS-CoV-2 S interaction that could treat COVID-19 infection....
BioCentury | Oct 27, 2020
Distillery Therapeutics

Peptide-based SARS-CoV-2 3CLpro inhibitor identified for COVID-19

DISEASE CATEGORY: Infectious disease INDICATION: Coronavirus A peptide-based inhibitor of the protease SARS-CoV-2 3CLpro could treat COVID-19. Synthesis and screening of a combinatorial library of fluorogenic substrates with glutamine in the P1 position, and varied natural...
BioCentury | Sep 30, 2020
Distillery Therapeutics

Endogenous bile acid identified for obesity and diabetes

DISEASE CATEGORY: Endocrine/metabolic INDICATION: Obesity; diabetes GPBAR1 agonism via cholic acid-7-sulfate, a gut-restricted endogenous bile acid, could treat obesity and Type II diabetes. In people who had undergone sleeve gastronomy, post-surgery fecal samples had higher levels...
Items per page:
1 - 10 of 3059